Axantia Is Driven By A Shared Mission To Provide Dependable Access To High-Quality And Affordable Medicines, Catering To The Needs Of The People Who Rely On Our Products In Their Daily Lives.
Exentia was launched in 2014 as a joint venture between the Abu Al-Haj family and Al-Faisaliah Group. It develops, manufactures, markets and distributes generic (methylated) medicines and industrial licensed preparations in more than 20 countries in the Middle East, Africa and the Commonwealth of Independent States (formerly the Soviet Union).
Axantia is a regional leader in high quality generic medicines, committed to improve health outcomes, cost of care, and the general wellbeing of patients
Our pursuit is to constantly achieve and accomplish visions and goals we have set. That is why we take a closer look at things, ask questions, and always think ahead
We know that our people are crucial to our success. Becoming a leading biopharmaceutical company depends on the potential, dedication, knowledge and performance of our employees and the excellence of our leaders.
We are concerned about the safety of our medications and we hold an effective pharmacovigilance system to ensure fulfilling our safety and ethical obligations toward our patients
Axantia develops, manufactures, markets, and distributes high quality branded generic pharmaceuticals and under licensed products in 20 countries across the Middle East, Africa, and the CIS.
We know that our people are crucial to our success. Becoming a leading biopharmaceutical company in the MENA region depends on the potential